Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

High Potency Active Pharmaceutical Ingredients (HPAPIs) is a niche segment of the pharmaceutical industry but yet it is the fastest growing segment. An API is classified as an HPAPI, which has an occupational exposure limit at or below 10 micrograms per cubic meter of air.

Statistics:

The global high potency active pharmaceutical ingredients market is estimated to account for US$ 21,165.50 Mn in 2020 and is expected to reach US$ 40,983.82 Mn by the end of 2027.

Global High Potency Active Pharmaceutical Ingredients Market: Drivers

Increasing prevalence of cancer is expected to propel growth of the global high potency active pharmaceutical ingredients market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. 

Moreover, R&D in antibody drug conjugate is also expected to aid in growth of the global high potency active pharmaceutical ingredients market. For instance, in June 2018, GlaxoSmithKline started a randomized study to assess the efficacy and safety of the antibody drug conjugate GSK2857916 in participants with multiple myeloma. In December 2019, the company announced that the data from the trial was submitted to the U.S. Food and Drug Administration for consideration for approval.

Statistics:

Innovative molecules segment held dominant position in the global high potency active pharmaceutical ingredients market in 2019, accounting for 70.3% share in terms of value, followed by generic molecules, respectively.

Figure 1. Global High Potency Active Pharmaceutical Ingredients Market Share (%), by Value, by Molecule Type, 2019

High Potency Active Pharmaceutical Ingredients  | Coherent Market Insights

Global High Potency Active Pharmaceutical Ingredients Market: Restraints

Conservative approach towards the acceptance of new and expensive drugs is expected to hinder growth of the global high potency active pharmaceutical ingredients market. Both patients and physicians alike, refrain from trying out a new product that is introduced in the market. Market penetration has a huge impact initially due to patient and physician preference patterns; however, it would have less impact in the future when the product is established in the market. At the present condition, high potency active pharmaceutical ingredient is new technology and will take time capturing the market and thus it will act as a restraint in the development and growth of the market.

Moreover, need for large capital investment in R&D of high potency active pharmaceutical ingredients is also expected to limit growth of the market.

request-sample

High Potency Active Pharmaceutical Ingredients Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 21,165.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.9% 2027 Value Projection: US$ 40,983.8 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Molecule Type: Innovative, Generic.
  • By Production Technology: Chemical Synthesis, Biotechnology.
  • By Application: Oncology, Hormonal, Glaucoma, Others.
Companies covered:

Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Services, Cambrex Corporation, Minakem, and Sanofi Aventis

Growth Drivers:
  • Technological advancement
  • Increasing product launches
Restraints & Challenges:
  • High costs
  • Stringent regulations

Global High Potency Active Pharmaceutical Ingredients Market: Opportunities 

Initiatives to address challenges in the high potency active pharmaceutical ingredients industry is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2020, Highly Potent Active Pharmaceutical Ingredients conference was announced to be held in May 2020 in London to discuss the challenges of the high potency active pharmaceutical ingredients industry.

Moreover, increasing number of solid oral dosage drug product manufacturing facilities is also expected to aid in growth of the market. For instance, in September 2020, Piramal Pharma Solutions held a grand opening event at their recently acquired solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania.

The global high potency active pharmaceutical ingredients market was valued at US$ 19,258.8 Mn in 2019 and is forecast to reach a value of US$ 40,983.82 Mn by 2027 at a CAGR of 9.9% between 2020 and 2027.

Figure 2. Global High Potency Active Pharmaceutical Ingredients Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

High Potency Active Pharmaceutical Ingredients  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global high potency active pharmaceutical ingredients market are focused on expanding their production capacity to enhance their market share. For instance, in September 2020, MilliporeSigma announced a US$ 65 million expansion of its high potency active pharmaceutical ingredient and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.

Major players in the market are also focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in July 2020, Piramal Pharma Solutions announced that it is providing Bolt Biotherapeutics with the supply of both the BDC-1001 ISAC drug substance and the drug product for Bolt’s ongoing Phase 1/2 clinical study in cancer patients.

Global High Potency Active Pharmaceutical Ingredients Market: Competitive Landscape

Major players operating in the global high potency active pharmaceutical ingredients market include, Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Covidien Plc, Merck & Co, Bayer AG, MilliporeSigma, SEQENS, Ajinomoto Bio-Pharma Services, Cambrex Corporation, Minakem, and Sanofi Aventis.

Global High Potency Active Pharmaceutical Ingredients Market: Key Developments

Major players in the global high potency active pharmaceutical ingredients market are focused on expanding their production capacity to enhance their market share. For instance, in August 2020, Ajinomoto Bio-Pharma Services expanded small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India.

Similarly, in April 2019, Cambrex Corporation completed the construction of a US$ 24 million high potency active pharmaceutical ingredient manufacturing facility at its site in Charles City, IA.

High potency active pharmaceutical ingredients (HPAPIs) are small-molecule, biologic, or hybrids of antibody–drug conjugates, which link a cytotoxic small-molecule to a monoclonal antibody. Demand for high potency active pharmaceutical ingredients (HPAPIs) is rapidly increasing due to its ability to target diseased cells more precisely and selectively than other APIs and is regarded as a relatively more efficient treatment for cancer and chronic diseases such as diabetes and heart diseases, worldwide. According to estimates from the International Agency for Research on Cancer (IARC), in 2012, 14.1 million new cancer cases and 8.2 million cancer deaths were recorded worldwide. This global burden of cancer is expected to account for 21.7 million new cancer cases and cause 13 million deaths by 2030.

Restraints of the Global High Potency Active Pharmaceutical Ingredients Market

Major factors hampering the growth of the high potency active pharmaceutical ingredients market during the forecast period constitutes of high costs, and stringent regulations.

Key features of the study:

  • This report provides in-depth analysis of the global high potency active pharmaceutical ingredients market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global high potency active pharmaceutical ingredients market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Molecule Types, Cambrex Corporation, Minakem, and Sanofi Aventis.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global high potency active pharmaceutical ingredients market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type:
    • Innovative
    • Generic
  • Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology:
    • Chemical Synthesis
    • Biotechnology
  • Global High Potency Active Pharmaceutical Ingredients Market, By Application:
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • Global High Potency Active Pharmaceutical Ingredients Market, By Geography:
    • North America
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Molecule Type
        • Innovative
        • Generic
      • By Production Technology
        • Chemical Synthesis
        • Biotechnology
      • By Application
        • Oncology
        • Hormonal
        • Glaucoma
        • Others
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Lonza Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Novartis International AG
    • BASF AG
    • SEQENS
    • Carbogen Amcis AG
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Roche Diagnostics
    • Boehringer Ingelheim
    • Other Players

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Molecule Type
      • Market Snippet, By Production Technology
      • Market Snippet, By Application
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Innovative
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Generic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Chemical Synthesis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Biotechnology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global High Potency Active Pharmaceutical Ingredients Market, By Application, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hormonal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Glaucoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global High Potency Active Pharmaceutical Ingredients Market, By Regions, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Lonza Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • BASF AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • SEQENS
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Carbogen Amcis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Roche Diagnostics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Other Players
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 24 figures on “High Potency Active Pharmaceutical Ingredients Market – Global forecast to 2027.

Frequently Asked Questions

The global high potency active pharmaceutical ingredients market estimated to reach a value of US$ 40,983.82 Mn by 2027 at a CAGR of 9.9% between 2020 and 2027.
Major factor driving the growth of global high potency active pharmaceutical ingredients market during the forecast period include technological advancement, and increasing product launches.
Major factors hampering the growth of the high potency active pharmaceutical ingredients market during the forecast period constitutes of high costs, and stringent regulations.
Innovative molecules held dominant position in the global high potency active pharmaceutical ingredients market in 2019.
North America High Potency Active Pharmaceutical Ingredients market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Services, Cambrex Corporation, Minakem, and Sanofi Aventis.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner